Cytovia’s parent Cytovia Holdings has disclosed plans to go public by merging with Isleworth Healthcare Acquisition Corp., a SPAC based in St. Petersburg, FL, in a deal expected to be completed in the third quarter. Upon completion, Isleworth will be renamed Cytovia Therapeutics, and continue researching, developing, and manufacturing therapies based on its complementary natural killer (NK) cell and NK engager antibody platforms . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge